We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28
weeks improves liver histology in diabetic patients with biopsy-proven NASH.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Indiana University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)